Glenmark Pharmaceuticals Limited — Updates, 05-05-2025: Press Release

Glenmark’s biotech arm, Ichnos Glenmark Innovation, received U.S. FDA Fast Track designation for ISB 2001, a trispecific antibody targeting difficult-to-treat multiple myeloma. Early trial results demonstrated strong efficacy and safety, supporting accelerated development. This positions ISB 2001 as a promising new therapy for patients who have exhausted existing options, with more data expected to bolster its clinical potential.